Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00152193-200402000-00018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Engineering Saccharomyces cerevisiae for medical applications.
Microb Cell Fact
January 2025
Chair of Biochemistry of Microorganisms, Faculty of Life Sciences: Food, Nutrition and Health, University of Bayreuth, 95326, Kulmbach, Germany.
Background: During the last decades, the advancements in synthetic biology opened the doors for a profusion of cost-effective, fast, and ecologically friendly medical applications priorly unimaginable. Following the trend, the genetic engineering of the baker's yeast, Saccharomyces cerevisiae, propelled its status from an instrumental ally in the food industry to a therapy and prophylaxis aid.
Main Text: In this review, we scrutinize the main applications of engineered S.
Biomarkers.
Alzheimers Dement
December 2024
Department of Psychosomatic Medicine, Rostock University Medical Center, Rostock, Germany.
Background: With a global ageing population, there is an increasing demand for fast and reliable early diagnosis of individuals. Convolutional neural networks (CNNs) have an immense potential in assisting clinicians in diagnosing dementia. Regional atrophy patterns, which are visible in T1-weighted MRI scans, have been consistently identified by the CNNs with high accuracy.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, FL, USA.
Background: The burden of Alzheimer's disease and related dementias is growing fast in Africa. The Recruitment and Retention for Alzheimer's Disease Diversity Genetic Cohorts in the Alzheimer's Disease Sequencing Project (READD-ADSP) has commenced recruitment of 5000 African participants (AD and cognitively unimpaired individuals) to generate genomic and biomarker data to better characterize AD genetic architecture in Africa. Participating countries, part of the African Dementia Consortium (AfDC) include Nigeria, Ghana, Benin, Cameroon, Uganda, Kenya, Ethiopia, Tanzania, and Mozambique.
View Article and Find Full Text PDFBackground: After the landmark approval of the Aβ-lowering antibody for treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease (AD), it has intensified the need to stratify patients based on the likelihood that they will benefit from any amyloid-lowering treatments currently in the pipeline. We therefore seek to identify individuals most likely to benefit from Aβ-lowering drugs by estimating intervention effect based on counterfactual reasoning for longitudinal cognitive decline at the individual level.
Method: We utilized 3,542 T1-weighted magnetic resonance images from the Alzheimer's Disease Neuroimaging Initiative (ADNI), involving 3,103 Alzheimer's patients and 439 cognitively normal individuals.
Public Health.
Alzheimers Dement
December 2024
Pacific Brain Health Center, Pacific Neuroscience Institute and Foundation, Santa Monica, CA, USA.
Background: The Coaching for Cognition in Alzheimer's (COCOA) Trial was a prospective RCT testing a remotely coached multimodal lifestyle intervention for participants early on the Alzheimer's disease spectrum. Intervention focused on diet, exercise, cognitive training, sleep, stress, and social engagement. Enrollment criteria targeted individuals with cognitive decline who were able to engage remotely with a professional coach.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!